Eckert & Ziegler Forge Alliance with Telix Pharmaceuticals for Actinium-225

Eckert & Ziegler SE, a company listed on TecDAX, has entered a collaboration and licence agreement with Telix Pharmaceuticals Limited. This partnership focuses on using Eckert & Ziegler’s cyclotron-based technology for producing Actinium-225 (Ac-225). The agreement includes milestone payments of up to €20 million to Eckert & Ziegler over the next two years.

This collaboration marks a strategic step for Eckert & Ziegler in positioning itself as a key supplier of Ac-225 in the radiopharmaceutical sector. The agreement aims to address the growing demand projected over the next decade. Currently, Ac-225 is in clinical trials for cancers such as prostate tumors and leukemia, but its availability remains limited.